Results 141 to 150 of about 2,000 (177)

Twice-Yearly Lenacapavir for HIV Prevention in Men and Gender-Diverse Persons

New England Journal of Medicine
BACKGROUND Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender women, transgender men, and
Colleen Kelley, Jesse Clark, Aditya Gaur   +2 more
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Lenacapavir: A capsid inhibitor for HIV-1 treatment and prevention

Biochemical Pharmacology
Lenacapavir (GS-6207) is a capsid inhibitor approved for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced people with multidrug-resistant HIV-1.
Ewelina Król, Guangdi Li, Erik de Clercq   +2 more
exaly   +2 more sources

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women.

New England Journal of Medicine
BACKGROUND There are gaps in uptake of, adherence to, and persistence in the use of preexposure prophylaxis for human immunodeficiency virus (HIV) prevention among cisgender women.
L. Bekker, Moupali Das, Quarraisha Abdool Karim, Khatija Ahmed, Joanne Batting, W. Brumskine, K. Gill, Ishana Harkoo, M. Jaggernath, G. Kigozi, N. Kiwanuka, P. Kotze, L. Lebina, Cheryl E. Louw, Moelo Malahleha, Mmatsie Manentsa, L. Mansoor, D. Moodley, V. Naicker, L. Naidoo, Megeshinee Naidoo, G. Nair, Nkosiphile Ndlovu, T. Palanee-Phillips, R. Panchia, Saresha Pillay, D. Potloane, P. Selepe, Nishanta Singh, Y. Singh, E. Spooner, Amy Ward, Zwelethu Zwane, Ramin Ebrahimi, Yang Zhao, Alexander Kintu, C. Deaton, Christoph C. Carter, J. Baeten, Flavia Matovu Kiweewa   +39 more
semanticscholar   +2 more sources

Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study

Lancet, The
BACKGROUND Long-acting antiretrovirals can address barriers to HIV pre-exposure prophylaxis (PrEP), such as stigma and adherence. In two phase 3 trials, twice-yearly subcutaneous lenacapavir was safe and highly efficacious for PrEP in diverse populations.
Christoph Carter, Jenna Yager, John Ling   +2 more
exaly   +2 more sources

Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial.

Clinical Infectious Diseases
BACKGROUND Lenacapavir is a long-acting HIV-1 capsid inhibitor for treatment of HIV-1 infection. We evaluated the efficacy and safety of lenacapavir in combination with an investigator-selected optimized background regimen (OBR) after 104 weeks in adults
O. Ogbuagu, Jean-Michel Molina, P. Chetchotisakd, M. Ramgopal, William E. Sanchez, J. Brunetta, Francesco Castelli, G. Crofoot, Chien-Ching Hung, S. Ronot-Bregigeon, N. Margot, Hui Wang, H. Dvory‐Sobol, Martin S Rhee, S. Segal-maurer   +14 more
semanticscholar   +2 more sources